Challenges and opportunities for non-antibody scaffold drugs

Drug Discovery Today

Volumn 20, Issue 10, 2015, Pages 1271-1283

  Vazquez Lombardi, Rodrigo ^a,b   Phan, Tri Giang ^a,b   Zimmermann, Carsten ^c   Lowe, David ^d   Jermutus, Lutz ^d,e   Christ, Daniel ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SAN DIEGO   (United States)

^d MEDIMMUNE   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 220; COMPLEMENT COMPONENT C1S INHIBITOR; DEPELESTAT; ECALLANTIDE; ICATIBANT; NON ANTIBODY SCAFFOLD; PEGDINETANIB; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; PROTEIN;

ANGIONEUROTIC EDEMA; BLOOD VESSEL PERMEABILITY; CLINICAL STUDY; COMPARATIVE STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG PENETRATION; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOGENICITY; MOLECULAR WEIGHT; NONHUMAN; PHAGE DISPLAY; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; PLASMA HALF LIFE; POSITRON EMISSION TOMOGRAPHY; PROTEIN DOMAIN; PROTEIN ENGINEERING; REVIEW; ANIMAL; DRUG DESIGN;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PROTEINS;

EID: 84944441863     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.09.004     Document Type: Review

References (189)

1. A.L. Nelson, and et al. Development trends for human monoclonal antibody therapeutics Nat. Rev. Drug Discov. 9 2010 767 774
2. L.G. Presta Molecular engineering and design of therapeutic antibodies Curr. Opin. Immunol. 20 2008 460 470
3. R. Rouet, and et al. Stability engineering of the human antibody repertoire FEBS Lett. 588 2014 269 277
4. J.R. Birch, and A.J. Racher Antibody production Adv. Drug Deliv. Rev. 58 2006 671 685
5. R. Rouet, and et al. Expression of high-affinity human antibody fragments in bacteria Nat. Protoc. 7 2012 364 373
6. A. Skerra Alternative non-antibody scaffolds for molecular recognition Curr. Opin. Biotechnol. 18 2007 295 304
7. H.K. Binz, and et al. Engineering novel binding proteins from nonimmunoglobulin domains Nat. Biotechnol. 23 2005 1257 1268
8. J. Löfblom, and et al. Non-immunoglobulin based protein scaffolds Curr. Opin. Biotechnol. 22 2011 843 848
9. R.E. Kontermann Strategies for extended serum half-life of protein therapeutics Curr. Opin. Biotechnol. 22 2011 868 876
10. J. Lofblom, and et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications FEBS Lett. 584 2010 2670 2680
11. D.C. Roopenian, and S. Akilesh FcRn: the neonatal Fc receptor comes of age Nat. Rev. Immunol. 7 2007 715 725
12. D. Sleep, and et al. Albumin as a versatile platform for drug half-life extension Biochim. Biophys. Acta 1830 2013 5526 5534
13. P.J. Carter Introduction to current and future protein therapeutics: a protein engineering perspective Exp. Cell Res. 317 2011 1261 1269
14. I.C. Wilkinson, and et al. Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure MAbs 5 2013 406 417
15. V.P. Chauhan, and et al. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies Annu. Rev. Chem. Biomol. Eng. 2 2011 281 298
16. T. Lammers, and et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Control. Release 161 2012 175 187
17. K.D. Wittrup, and et al. Practical theoretic guidance for the design of tumor-targeting agents Methods Enzymol. 503 2012 255 268
18. D.K. Shah, and A.M. Betts Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human MAbs 5 2013 297 305
19. A. Orlova, and et al. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model J. Nucl. Med. 50 2009 417 425
20. C. Zahnd, and et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size Cancer Res. 70 2010 1595 1605
21. A. Natarajan, and et al. A novel engineered anti-CD20 tracer enables early time PET imaging in a humanized transgenic mouse model of B-cell non-hodgkins lymphoma Clin. Cancer Res. 19 2013 6820 6829
22. C.T. Mendler, and et al. High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation MAbs 7 2015 96 109
23. N. Bien-Ly, and et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants J. Exp. Med. 211 2014 233 244
24. R.J. Watts, and M.S. Dennis Bispecific antibodies for delivery into the brain Curr. Opin. Chem. Biol. 17 2013 393 399
25. S.J. Henderson, and et al. Sustained peripheral depletion of amyloid-beta with a novel form of neprilysin does not affect central levels of amyloid-beta Brain 137 2014 553 564
26. C. Vaccaro, and et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels Nat. Biotechnol. 23 2005 1283 1288
27. M.W. Traxlmayr, and et al. Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display Protein Eng. Des. Sel. 26 2013 255 265
28. M. Woisetschläger, and et al. In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites Biotechnol. J. 9 2014 844 851
29. K. Dudgeon, and et al. General strategy for the generation of human antibody variable domains with increased aggregation resistance Proc. Natl. Acad. Sci. U. S. A. 109 2012 10879 10884
30. K. Dudgeon, and et al. Sequence determinants of protein aggregation in human VH domains Protein Eng. Des. Sel. 22 2009 217 220
31. D. Christ, and et al. Repertoires of aggregation-resistant human antibody domains Protein Eng. Des. Sel. 20 2007 413 416
32. A.A. Shukla, and J. Thommes Recent advances in large-scale production of monoclonal antibodies and related proteins Trends Biotechnol. 28 2010 253 261
33. J.L. Corchero, and et al. Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics Biotechnol. Adv. 31 2013 140 153
34. C. Stevenson, and et al. Delivery of peptides and proteins via long acting injections and implants J.C. Wright, D.J. Burgess, Long Acting Injections and Implants 2012 Springer 409 427
35. C. Zahnd, and et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2 J. Mol. Biol. 369 2007 1015 1028
36. A. Jonsson, and et al. Engineering of a femtomolar affinity binding protein to human serum albumin Protein Eng. Des. Sel. 21 2008 515 527
37. Available at: http://www.intarcia.com/.
38. S.D. Putney, and P.A. Burke Improving protein therapeutics with sustained-release formulations Nat. Biotechnol. 16 1998 153 157
39. Y.S. Jung, and et al. Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis J. Control. Release 171 2013 143 151
40. S.M. Lewis, and et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface Nat. Biotechnol. 32 2014 191 198
41. R. Rouet, and D. Christ Bispecific antibodies with native chain structure Nat. Biotechnol. 32 2014 136 137
42. C. Spiess, and et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies Nat. Biotechnol. 31 2013 753 758
43. H. Byrne, and et al. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications Trends Biotechnol. 31 2013 621 632
44. S.L. Emanuel, and et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor MAbs 3 2011 38 48
45. F. Fleetwood, and et al. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity Scientific Rep. 4 2014 7518
46. D. Grabulovski, and et al. COVA322: overcoming limitations of current biologics in rheumatoid arthritis by a novel, bispecific tumor-necrosis-factor-alpha/interleukin-17A (TNF/IL-17A) inhibitor moving towards the clinic Arthritis Rheumat. 65 2013 S544
47. J. Le Couter, and J.M. Scheer Bispecific therapeutics for ophthalmic indications: target selection and the optimal molecular format Exp. Rev. Ophthalmol. 9 2014 217 225
48. S. Schlehuber, and A. Skerra Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold Biol. Chem. 382 2001 1335 1342
49. J. Silverman, and et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains Nat. Biotechnol. 23 2005 1556 1561
50. F. Yu, and et al. An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo MAbs 6 2014 1598 1607
51. J.B. Spangler, and et al. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression J. Mol. Biol. 422 2012 532 544
52. A. Nowakowski, and et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody Proc. Natl. Acad. Sci. U. S. A. 99 2002 11346 11350
53. C. Spiess, and et al. Alternative molecular formats and therapeutic applications for bispecific antibodies Mol. Immunol. 67 2015 95 106
54. E. Dhimolea, and J.M. Reichert World bispecific antibody summit, September 27-28, 2011, Boston, MA MAbs 4 2012 4 13
55. G. Schaefer, and et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies Cancer Cell 20 2011 472 486
56. C.F. McDonagh, and et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3 Mol. Cancer Ther. 11 2012 582 593
57. A.D. Pardee, and et al. Integrating costimulatory agonists to optimize immune-based cancer therapies Immunotherapy 1 2009 249 264
58. C.J. Hutchings, and et al. Monoclonal anti-beta -adrenergic receptor antibodies activate G protein signaling in the absence of beta-arrestin recruitment MAbs 6 2013 246 261
59. J.R. Adair, and et al. Antibody-drug conjugates - a perfect synergy Exp. Opin. Biol. Ther. 12 2012 1191 1206
60. J.S. Swers, and et al. Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis Mol. Cancer Ther. 12 2013 1235 1244
61. H. Chen, and et al. Abstract 239: a novel multimeric protein scaffold stimulates apoptotic signaling through TRAILR2 Cancer Res. 7 Suppl. 8 2012 239
62. J. Duan, and et al. Fibronectin type III domain based monobody with high avidity Biochemistry 46 2007 12656 12664
63. C. Chittasupho Multivalent ligand: design principle for targeted therapeutic delivery approach Ther. Deliv. 3 2012 1171 1187
64. V. Oganesyan, and et al. Fibronectin type III domains engineered to bind CD40L: cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of two complexes Acta Crystallogr. F: Struct. Biol. Cryst. Commun. 69 2013 1045 1048
65. K.D. Ratanji, and et al. Immunogenicity of therapeutic proteins: influence of aggregation J. Immunotoxicol. 11 2013 99 109
66. H. Saber, and J.K. Leighton An FDA oncology analysis of antibody-drug conjugates Reg. Toxicol. Pharmacol. 71 2015 444 452
67. R.J. Kreitman, and I. Pastan Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox Clin. Cancer Res. 17 2011 6398 6405
68. R.P. Lyon, and et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index Nat. Biotechnol. 33 2015 733 735
69. Y.T. Adem, and et al. Auristatin antibody drug conjugate physical instability and the role of drug payload Bioconjugate Chem. 25 2014 656 664
70. D. Berndorff, and et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate Clin. Cancer Res. 11 2005 7053 7063
71. H. Merten, and et al. Antibody drug conjugates for tumor targeting - novel conjugation chemistries and the promise of non-IgG binding proteins Bioconjugate Chem. 2015 10.1021/acs.bioconjchem.5b00260
72. R.H. Kimura, and et al. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects Cancer Res. 69 2009 2435 2442
73. L. Jiang, and et al. 64Cu-labeled divalent cystine knot peptide for imaging carotid atherosclerotic plaques J. Nucl. Med. 56 2015 939 944
74. L. Jiang, and et al. Evaluation of a 64Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing αvβ3 integrin J. Nucl. Med. 51 2010 251 258
75. K. Josephson, and et al. mRNA display: from basic principles to macrocycle drug discovery Drug Discov. Today 19 2014 388 399
76. A.J. Hooper, and J.R. Burnett Anti-PCSK9 therapies for the treatment of hypercholesterolemia Exp. Opin. Biol. Ther. 13 2013 429 435
77. A. Mullard Cholesterol-lowering blockbuster candidates speed into Phase III trials Nat. Rev. Drug Discov. 11 2012 817 819
78. A.W. Tolcher, and et al. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin Clin. Cancer Res. 17 2011 363 371
79. J.D. Waters, and et al. CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy J. Neurooncol. 110 2012 37 48
80. S. Ahlgren, and et al. Targeting of HER2-expressing tumors using In-111-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold J. Nucl. Med. 51 2010 1131 1138
81. M. Friedman, and et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor Protein Eng. Des. Sel. 20 2007 189 199
82. J. Li, and et al. Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor Biotechnol. Appl. Biochem. 55 2010 99 109
83. M. Lindborg, and et al. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo J. Mol. Biol. 407 2011 298 315
84. M. Malm, and et al. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification PLoS One 8 2013 e62791
85. H. Ebersbach, and et al. Affilin-novel binding molecules based on human gamma-B-crystallin, an all 13-sheet protein J. Mol. Biol. 372 2007 172 185
86. E. Fiedler, and et al. Ubiquitin or Gamma-crystalline Conjugates for use in therapy, Diagnosis and Chromatography 2010 U.S. Patent. 7,838,629
87. A. Richter, and et al. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins FEBS Lett. 588 2013 213 218
88. K. Mross, and et al. Abstract A212: First in human phase I study of PRS-050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: Results of a dose escalation study Mol. Cancer Ther. 10 Suppl. 11 2011 A212
89. S.A. Olwill, and et al. A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity Mol. Cancer Ther. 12 2013 2459 2471
90. D. Schoenfeld, and et al. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies Proc. Natl. Acad. Sci. U. S. A. 106 2009 8198 8203
91. K. Jensen, and et al. Muteins of Tear Lipocalin and Methods for obtaining the same 2013 US Patent 20,130,017,996
92. A.G.T. van Scheltinga, and et al. In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer J. Nucl. Med. 55 2014 665 671
93. J. Rohn Anaphore Nat. Biotechnol. 28 2010 1143
94. J.E. Allen, and et al. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes Mol. Cancer Ther. 11 2012 2087 2095
95. C. Thogersen, and J. Holldack A tetranectin-based platform for protein engineering Innov. Pharm. Technol 2006 27 30 http://www.iptonline.com/articles/public/IPT-18-pg27-31-2005.pdf
96. M. Braddock 11th Annual inflammatory and immune diseases drug discovery and development summit: 12-13 March 2007, San Francisco, USA Exp. Opin. Investig. Drugs 16 2007 909 917
97. A. Angelini, and et al. Bicyclic peptide inhibitor reveals large contact interface with a protease target ACS Chem. Biol. 7 2012 817 821
98. V. Baeriswyl, and et al. Bicyclic peptides with optimized ring size inhibit human plasma kallikrein and its orthologues while sparing paralogous proteases ChemMedChem 7 2012 1173 1176
99. C. Heinis, and et al. Phage-encoded combinatorial chemical libraries based on bicyclic peptides Nat. Chem. Biol. 5 2009 502 507
100. P. Diderich, and C. Heinis Phage selection of bicyclic peptides binding Her2 Tetrahedron 70 2014 7733 7739
101. M.D. Diem, and et al. Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop positions Protein Eng. Des. Sel. 27 2014 419 429
102. H. Kolmar Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins FEBS J. 275 2008 2684 2690
103. S. Aldridge Deal validates DARPins Nat. Biotechnol. 30 2012 1014
104. M.T. Stumpp, and et al. DARPins: a new generation of protein therapeutics Drug Discov. Today 13 2008 695 701
105. S. Wolf, and et al. Phase I Mp0112 Wet AMD Study: results of a single escalating dose study with DARPin(R) MP0112 in wet AMD ARVO Meeting Abstracts 52 2011 1655
106. M. Patel, and et al. Single ascending doses of DARPin(R), MP0112, show potential for quarterly dosing in DME ARVO Meeting Abstracts 52 2011 582
107. D. Grabulovski, and et al. A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties J. Biol. Chem. 282 2007 3196 3204
108. L. Devy, and et al. PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor Neoplasia 9 2007 927 937
109. F.K. Dunlevy, and et al. Anti-inflammatory effects of DX-890, a human neutrophil elastase inhibitor J. Cys. Fibros. 11 2012 300 304
110. F. Saudubray, and et al. Phase IIa clinical study of a new human neutrophil elastase inhibitor (hNE), EPI hNE4 (DX-890), with repeated administration by inhalation in adult cystic fibrosis patients J. Cyst. Fibros. 2 2003 A85
111. C.J. Scott, and C.C. Taggart Biologic protease inhibitors as novel therapeutic agents Biochimie 92 2010 1681 1688
112. J.D. Steemson, and et al. Tracking molecular recognition at the atomic level with a new protein scaffold based on the OB-fold PLoS One 9 2014 e86050
113. C.S. Mintz, and R. Crea Protein scaffolds BioProcess Int. 11 2013 2
114. E.V. Getmanova, and et al. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro Chem. Biol. 13 2006 549 556
115. M. Parker, and et al. Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two Protein Eng. Des. Sel. 18 2005 435 444
116. B.J. Hackel, and et al. Stability and CDR composition biases enrich binder functionality landscapes J. Mol. Biol. 401 2010 84 96
117. J. Feldwisch, and et al. Design of an optimized scaffold for affibody molecules J. Mol. Biol. 398 2010 232 247
118. M. Friedman, and et al. Engineering and characterization of a bispecific HER2× EGFR-binding affibody molecule Biotechnol. Appl. Biochem. 54 2009 121 131
119. E. Wahlberg, and et al. An affibody in complex with a target protein: structure and coupled folding Proc. Natl. Acad. Sci. U. S. A. 100 2003 3185 3190
120. R.P. Baum, and et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic In-111- or Ga-68-labeled Affibody molecules J. Nucl. Med. 51 2010 892 897
121. S. Lorey, and et al. Novel ubiquitin-derived high affinity binding proteins with tumor targeting properties J. Biol. Chem. 289 2014 8493 8507
122. E. Eggenstein, and et al. Structure-guided engineering of Anticalins with improved binding behavior and biochemical characteristics for application in radio-immuno imaging and/or therapy J. Struct. Biol. 185 2014 203 214
123. S. Schlehuber, and A. Skerra Tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant - a so-called 'anticalin' - using a molecular random approach Biophys. Chem. 96 2002 213 228
124. J. Wiedersich, and et al. Temperature and pressure dependence of protein stability: the engineered fluorescein-binding lipocalin FluA shows an elliptic phase diagram Proc. Natl. Acad. Sci. U. S. A. 105 2008 5756 5761
125. K. Mross, and et al. First-in-human Phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors PLoS One 8 2013 e83232
126. P. Byla, and et al. Selection of a novel and highly specific tumor necrosis factor alpha (TNF alpha) antagonist: insight from the crystal structure of the antagonist-TNFalpha complex J. Biol. Chem. 285 2010 12096 12100
127. A. Angelini, and et al. Chemical macrocyclization of peptides fused to antibody Fc fragments Bioconjugate Chem. 23 2012 1856 1863
128. A. Angelini, and et al. Bicyclization and tethering to albumin yields long-acting peptide antagonists J. Med. Chem. 55 2012 10187 10197
129. A. Christmann, and et al. The cystine knot of a squash-type protease inhibitor as a structural scaffold for Escherichia coli cell surface display of conformationally constrained peptides Protein Eng. 12 1999 797 806
130. I. Sermadiras, and et al. Recombinant expression and in vitro characterisation of active huwentoxin-IV PLoS One 8 2013 e83202
131. S.J. Moore, and et al. Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma Proc. Natl. Acad. Sci. U. S. A. 110 2013 14598 14603
132. A. Heitz, and et al. Knottin cyclization: impact on structure and dynamics BMC Struct. Biol. 8 2008 54
133. Y.A. Muller, and et al. The cystine knot promotes folding and not thermodynamic stability in vascular endothelial growth factor J. Biol. Chem. 277 2002 43410 43416
134. Z. Miao, and et al. An engineered knottin peptide labeled with 18F for PET imaging of integrin expression Bioconjugate Chem. 20 2009 2342 2347
135. H.K. Binz, and et al. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins J. Mol. Biol. 332 2003 489 503
136. P.A. Campochiaro, and et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a Phase 1/2 study Am. J. Ophthalmol. 155 2012 697 704
137. D. Schlatter, and et al. Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain MAbs 4 2012 497 508
138. M. Silacci, and et al. Linker length matters, Fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency J. Biol. Chem. 289 2014 14392 14398
139. W. Markland, and et al. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin Biochemistry 35 1996 8058 8067
140. W. Markland, and et al. Iterative optimization of high-affinity protease inhibitors using phage display. 1. Plasmin Biochemistry 35 1996 8045 8057
141. L. Schneider, and et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor J. Allergy Clin. Immunol. 120 2007 416 422
142. R. Gilbreth, and et al. Stabilization of the third fibronectin type III domain of human tenascin-C through minimal mutation and rational design Protein Eng. Des. Sel. 27 2014 411 418
143. M.M. Gompels, and et al. C1 inhibitor deficiency: consensus document Clin. Exp. Immunol. 139 2005 379 394 Corrigenda 141, 189-190.
144. J.H. Levy, and P.S. O'Donnell The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema Expert Opin. Investig. Drugs 15 2006 1077 1090
145. C.M. Lee, and et al. Selection of human antibody fragments by phage display Nat. Protoc. 2 2007 3001 3008
146. A.L. Sheffer, and et al. Ecallantide (DX-88) for acute hereditary angioedema attacks: Integrated analysis of 2 double-blind, phase 3 studies J. Allergy Clin. Immunol. 128 2011 153 239
147. S. Attucci, and et al. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis J. Pharmacol. Exp. Ther. 318 2006 803 809
148. D. Grimbert, and et al. Characteristics of EPI-hNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis J. Aerosol Medicine 16 2003 121 129
149. V. Tolmachev, and et al. A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue Eur. J. Nucl. Med. Mol. Imag. 37 2010 1356 1367
150. A. Orlova, and et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule Cancer Res. 66 2006 4339 4348
151. G. Neufeld, and et al. Vascular endothelial growth factor (VEGF) and its receptors FASEB J. 13 1999 9 22
152. R. Mamluk, and et al. Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2 MAbs 2 2010 199 208
153. J.M. Harris, and R.B. Chess Effect of pegylation on pharmaceuticals Nat. Rev. Drug Discov. 2 2003 214 221
154. D. Schiff, and et al. Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM) J. Clin. Oncol. 28 Suppl. 15 2010 2011
155. T. Mitchell, and et al. Pharmacologic profile of the adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering J. Pharmacol. Exp. Ther. 350 2014 412 424
156. E.A. Stein, and et al. LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study J. Am. Col. Cardiol. 63 2014 12-S
157. K. Ishihara, and T. Hirano IL-6 in autoimmune disease and chronic inflammatory proliferative disease Cytokine Growth Factor Reviews 13 2002 357 368
158. Available at: http://www.clinicaltrials.gov
159. T. Wurch, and et al. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept Trends Biotechnol. 30 2012 575 582
160. E. Nemeth Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias Adv. Hematol. 2010 2009
161. K. Jensen, and et al. Muteins of tear lipocalin and methods for obtaining the same 2007 Google Patents
162. Available at: http://www.pieris-ag.com
163. H. Gille, and et al. Discovery and characterization of a novel Anticalin with potent in vivo antagonistic activity towards VEGF-A Cancer Res. 68 Suppl. 9 2008 4077
164. A. Plückthun Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy Ann. Rev. Pharmacol. Toxicol. 55 2015 489 511
165. J.M. Reichert, and et al. 9th Annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland MAbs 6 2014 309 326
166. C. Heinis, and G. Winter Encoded libraries of chemically modified peptides Curr. Opin. Chem. Biol. 26 2015 89 98
167. E. De Genst, and et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies Proc. Natl. Acad. Sci. U. S. A. 103 2006 4586 4591
168. R. Rouet, and et al. Fully human VH single domains that rival the stability and cleft recognition of camelid antibodies J. Biol. Chem. 290 2015 11905 11917
169. D. Lipovsek Adnectins: engineered target-binding protein therapeutics Protein Eng. Des. Sel. 24 2011 3 9
170. A. Skerra Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities FEBS J. 275 2008 2677 2683
171. J. Desmet, and et al. Structural basis of IL-23 antagonism by an Alphabody protein scaffold Nat. Communications 5 2014 5237
172. J.D. Bloom, and et al. Structural determinants of the rate of protein evolution in yeast Mol. Biol. Evol. 23 2006 1751 1761
173. E. Dellus-Gur, and et al. What makes a protein fold amenable to functional innovation? Fold polarity and stability trade-offs J. Mol. Biol. 425 2013 2609 2621
174. Z. Miao, and et al. Protein scaffold-based molecular probes for cancer molecular imaging Amino Acids 41 2011 1037 1047
175. G.M. Thurber, and et al. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance Adv. Drug Deliv. Rev. 60 2008 1421 1434
176. M.M. Schmidt, and K.D. Wittrup A modeling analysis of the effects of molecular size and binding affinity on tumor targeting Mol. Cancer Ther. 8 2009 2861 2871
177. F. Yuan, and et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res. 55 1995 3752 3756
178. M. Pruszynski, and et al. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling J. Nucl. Med. 55 2014 650 656
179. B.J. Hackel, and et al. Designed hydrophilic and charge mutations of the fibronectin domain: towards tailored protein biodistribution Protein Eng. Des. Sel. 25 2012 639 647
180. R.H. Kimura, and et al. Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer Clin. Cancer Res. 18 2012 839 849
181. T.A. Tran, and et al. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules Bioconjugate Chem. 19 2008 2568 2576
182. D.M. Goldenberg, and et al. Cancer imaging and therapy with bispecific antibody pretargeting Update Cancer Ther. 2 2007 19 31
183. M. Steiner, and et al. Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications Bioconjugate Chem. 24 2013 234 241
184. K. Mandal, and et al. Chemical synthesis and X-ray structure of a heterochiral {D-protein antagonist plus vascular endothelial growth factor} protein complex by racemic crystallography Proc. Natl. Acad. Sci. U. S. A. 109 2012 14779 14784
185. H.M. Dintzis, and et al. A comparison of the immunogenicity of a pair of enantiomeric proteins Proteins 16 1993 306 308
186. A.L. Sheffer, and et al. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies J. Allergy Clin. Immunol. 128 2011 153 159
187. J.L. Martello, and et al. Ecallantide for treatment of acute attacks of hereditary angioedema Am. J. Health Syst. Pharm. 69 2012 651 657
188. R. Ponce, and et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies Regul. Toxicol. Pharmacol. 54 2009 164 182
189. V. Brinks, and et al. Preclinical models used for immunogenicity prediction of therapeutic proteins Pharm. Res. 30 2013 1719 1728